1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
MYUNGMOON Pharm Co., Ltd.

MYUNGMOON Pharm Co., Ltd.

KKRX:017180
1,198.00
KRW
-35.00
(-2.84%)
-76.37EPS
42.52BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4,872.73
4,913.92
5,883.57
6,174.4
5,480.9
5,961.38
5,961.79
4,366.83
4,073.89
4,505.27
5,021.62
5,591.13
5,871.98
5,948.73
Basic EPS, GAAP
48.2
35.49
-758.86
292.95
305.36
39.94
-814.44
-944
-203
233
-134
-91
57
-49.67
Free Cash Flow per Basic Share
-127.89
-135.8
-439.65
-167.77
-555.03
12.68
-682.25
-652.72
14.2
104.44
-241.99
-82.19
-256.7
-295.12
Dividend per Share
- -
12.58
14.71
14.05
45.14
96.59
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
3,316.01
3,354.19
3,073.18
3,761.28
3,901.38
3,581.72
3,055.72
2,579.48
2,374.06
2,648.13
2,489.11
2,897.28
2,953.8
2,919.27
Tangible Book Value per Share
2,817.35
2,929.14
2,913.19
3,688.09
3,833
3,509.26
3,015.61
2,556.86
2,366.74
2,638.71
2,481.14
2,881.46
2,939.67
2,904.42
Basic Weighted Avg Shares
21
21
21
23
26
25
25
29
34
34
34
33
33
34
Sales/Revenue/Turnover
103,723
105,421
125,101
142,180
140,138
147,499
149,346
127,853
137,760
152,135
169,567
186,443
195,247
199,825
Operating Margin (%)
3.96
3.53
-1.97
7.07
5.33
3.35
-9.57
-22.65
-4.27
4.23
0.57
1.03
3.5
0.76
Depreciation Expense
2,255
2,306
2,022
2,003
1,980
1,914
3,661
4,201
4,203
4,238
4,168
4,066
3,962
2,318
Net Income, GAAP
1,026
761
-16,135
6,746
7,807
988
-20,402
-27,639
-6,865
7,868
-4,525
-3,035
1,895
-1,669
Effective Tax Rate (%)
81.65
106.26
- -
20.93
19.54
82.68
- -
- -
- -
- -
- -
- -
46.46
- -
Profit Margin (%)
0.99
0.72
-12.9
4.74
5.57
0.67
-13.66
-21.62
-4.98
5.17
-2.67
-1.63
0.97
-0.83
Working Capital
-8,940
-5,243
-20,181
1,348
-7,983
-16,385
-32,641
-44,743
-45,622
-40,115
-34,937
-12,330
-4,291
7,009
LT Debt
102
1,922
620
186
3,093
9,473
24,814
7,702
5,956
7,304
13,044
35,329
43,134
21,764
Total Equity
73,197
73,152
67,120
94,680
101,719
93,064
80,196
90,775
85,874
95,267
88,755
103,123
104,457
102,640
Return on Invested Capital (%)
0.46
-0.14
- -
4.7
3.28
0.45
- -
- -
- -
- -
- -
- -
1.88
- -
Return on Capital (%)
1.6
0.81
- -
5.59
5.11
1.16
- -
- -
- -
- -
- -
- -
2.59
- -
Return on Common Equity (%)
1.51
1.11
-24.41
8.75
8.27
1.05
-24.55
-33.77
-8.2
9.27
-5.23
-3.37
1.94
-1.7

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
55,499
54,879
65,384
LT Borrowings
42,646
42,448
21,176
LT Finance Leases
488
415
587
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
33
33
33
Market Capitalization
61,842
61,308
42,521

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
92,072
93,413
118,408
Cash, Cash Equivalents & STI
6,145
4,560
24,305
Accounts Receivable, Net
42,868
43,190
46,152
Inventories
38,724
41,241
43,777
Total Current Liabilities
96,363
98,633
111,399
Payables & Accruals
- -
- -
- -
ST Debt
55,499
54,879
65,384
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.55%
3.24%
1.29%
Free Cash Flow
-508.44%
69.02%
211.43%
Net Income, GAAP
-298.51%
-128.54%
-162.46%
Sales/Revenue/Turnover
4.86%
8.86%
4.72%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
44,231
46,081
46,983
49,148
186,443
2025
45,875
48,757
49,862
50,753
195,247
2026
47,999
51,211
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-37
-46
-24
15.2
-91
2025
-58
103
-16.42
28.22
57
2026
-23.98
-37
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Cheol-Han Bae
Full Time Employees
309
Sector
Health technology
Industry
Pharmaceuticals: major
Address
7, Gangnam-daero Gangnam SL South Korea 06258
IPO Date
Jul 10, 2008
Website
mmpharm.co.kr
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
MYUNGMOON Pharm co.,Ltd engages in the research, development, manufacture, distribution, and sale of pharmaceutical products primarily in South Korea with international operations. Founded in 1983 and headquartered in Seoul, South Korea, the company produces a wide range of pharmaceutical products including ethical (ETC) drugs and over-the-counter (OTC) drugs. Its main product categories include anesthetic agents; digestive system drugs; rheumatoid arthritis remedies; central nervous system drugs; circulatory drugs; anti-depressant agents; anti-diabetic agents; antibiotics; hormone agents; narcotics; dermatology and urology drugs; muscle relaxants; anti-osteoporosis drugs; steroids; appetite suppressants; and carcinostatic substances. Its OTC portfolio comprises antinauseant agents; hepatics; immunologic agents; antidiarrheal agents; skin external preparations; antiallergic agents; muscle relaxants; cold remedies; parasiticides; health supplements; multiple vitamins; eye nutrition products; eye drops; and topical analgesics. The company manufactures medicines in diverse forms such as injections, tablets, capsules, aerosols, patches, solutions, and creams. It holds numerous product licenses exceeding 400 for specialized and general medicines. MYUNGMOON operates two factories certified under PIC/s GMP and opened a high-tech manufacturing facility in 2018. Recent developments include ongoing clinical trials and pipeline advances focused on treatments such as Midodrine Hydrochloride for orthostatic hypotension, with first approval granted in 2025. The company continues to expand its pharmaceutical innovations with new product launches and strategic research initiatives addressing various therapeutic areas. In addition to pharmaceuticals, MYUNGMOON also engages in ancillary business activities such as golf course operations. Its strategic focus combines manufacturing excellence, broad product offerings, and active research and development to maintain competitive positioning in the pharmaceutical industry at home and abroad. The company completed a merger with a wholly owned subsidiary in 2012, enhancing operational efficiencies. Overall, MYUNGMOON Pharm co.,Ltd represents a well-established and diversified pharmaceutical enterprise with a strong R&D pipeline, a comprehensive portfolio of prescription and OTC drugs, and a commitment to technology-driven manufacturing excellence.